Project CBD
MARCH 21, 2023
She was upset with herself for being so careless and concerned that the condition would persist. For many other people of all ages, tinnitus is indeed a chronic condition that has nothing to do with loud ‘80s cover bands in small clubs. And it’s not just ringing.
Veriheal
MARCH 20, 2023
The state bill would start the process of legalizing centers for veterans and first responders to receive psilocybin and MDMA (a synthetic psychedelic) to treat mental health conditions like PTSD. Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Missouri Rep.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
MARCH 2, 2024
In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.
Cannabis Law Report
MAY 31, 2022
The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Stay tuned… Oregon plans to accept applications for Facilitators, Laboratories, Manufacturers and Service Centers starting January 2023. Schedule I.
Cannabis Law Report
APRIL 21, 2022
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. Berra Yazar-Klosinski, Ph.D.
Cannabis Law Report
SEPTEMBER 22, 2021
Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023. The principal objective of Programme 3 is to identify a drug candidate(s) for neuropathic pain conditions.
Cannabis Law Report
OCTOBER 4, 2021
A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.
Expert insights. Personalized for you.
144 
Let's personalize your content